RRdog, I have added one more second-line NSCLC phase III trial to the list, for a total of 10. I also calculated the mean and standard deviation of the 10. It is amazing how after 12 years the original trial which was used to approve docetaxel has not really been improved upon.
The mouse study of bavi (3G4) and doce in breast cancer has an extensive discussion section that explores why bavi and docetaxel are uniquely synergistic.